Cyclic nucleotide signalling and cardiovascular pathophysiology

VANDECASTEELE Grégoire, DR2 Inserm : Team leader
LEBLAIS Véronique, PU Université-Paris-Saclay : Team leader
FISCHMEISTER Rodolphe, DRCE Emérite Inserm
LEROY Jérôme, PU Université-Paris-Saclay
MANOURY Boris, MCU Université-Paris-Saclay
MIKA Delphine, CR Inserm
PIDOUX Guillaume, CR Inserm
VARIN Audrey, IE Université-Paris-Saclay
BOSCIONE Alice, IE CDD
DAYDE Delphine, Post-doc
DONATE PUERTAS Rosa, Post-doc
BARTHOU Aurélien, PhD Student
JIN Valentin, PhD Student
TOTH Maeliss, PhD Student
 

The cyclic nucleotides (CN) cAMP and cGMP participate in the main regulations of cardiac function. They act as second messengers for sympathetic and parasympathetic systems, nitric oxide (NO) and natriuretic peptides. CN may exert beneficial or deleterious effects on the heart, depending on the duration of the stimulation. Acute elevation of CN regulate cardiac excitation-contraction coupling. However, chronic elevation of cAMP contributes to the development of cardiac hypertrophy and progression to heart failure (HF), while cGMP possesses anti-hypertrophic properties. Our work of the last four years has been dedicated to understanding the intracellular organization of CN pathways, which we found are highly compartmentalized, and the changes occurring in pathophysiological situations. The general objective is to understand the molecular mechanisms responsible for the homeostasis of these two second messengers and the functional consequences for cellular and cardiac function. We developed novel electrophysiological and imaging techniques to record simultaneously cyclic nucleotide changes and key functional parameters of the cardiac cell.